Pharma News

FDA Approves Tevimbra, BeiGene’s Treatment for Adults with Unresectable or Metastatic Esophageal Squamous Carcinoma

Tevimbra (tislelizumab-jsgr) has been approved as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma who have previously undergone systemic chemotherapy excluding PD-L1 inhibitors.

Source link
#FDA #Approves #Tevimbra #BeiGenes #Treatment #Adults #Unresectable #Metastatic #Esophageal #Squamous #Carcinoma

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *